Peristaltic Pump Ensures Repeatability
Watson-Marlow’s 120 cased peristaltic pumps are designed for single-use systems that require no contamination.
Watson-Marlow’s 120 cased peristaltic pumps are designed for single-use systems that require no contamination. The 120 pumps are compact and stackable and can be used for multiple feed applications such as pH control, antifoam, and nutrient and buffer addition. The 120 pumps offer accurate and repeatable pumping with a speed range of 2000:1, speed accuracy of ±1%, and a selection of USP Class VI tubes.
The 110 mm wide pumps feature a 114 pumphead with a spring-loaded flip-top track that ensures repetitive flow and pressure, and error-free tube changing. The IP31-rated 120 pumps are designed with illuminated numeric speed display that provides easy recording of operating parameters. A keypad lock prevents accidental commands. Three different models are available for fixed speed, manual, or remote auto control, and five single and multi-channel pumpheads.
Watson Marlowwww.watson-marlow.com/us-en
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Novartis Acquisition of Regulus Therapeutics is Complete
June 25th 2025A key property included in the acquisition is farabursen, an investigational next-generation oligonucleotide targeting the microRNA miR-17 with preferential kidney exposure, intended to treat people with autosomal dominant polycystic kidney disease.
